Show simple item record

dc.contributor.authorFlores, Kendra
dc.contributor.authorDinh, Kate
dc.contributor.authorRouleau, Erin
dc.contributor.authorWhalen, Giles F.
dc.contributor.authorWassef, Wahid Y.
dc.contributor.authorLaFemina, Jennifer
dc.date2022-08-11T08:10:13.000
dc.date.accessioned2022-08-23T17:00:14Z
dc.date.available2022-08-23T17:00:14Z
dc.date.issued2015-11-01
dc.date.submitted2016-11-09
dc.identifier.citationCancer Genet. 2015 Nov;208(11):559-63. doi: 10.1016/j.cancergen.2015.09.002. Epub 2015 Sep 24. <a href="http://dx.doi.org/10.1016/j.cancergen.2015.09.002">Link to article on publisher's site</a>
dc.identifier.issn2210-7762 (Print)
dc.identifier.doi10.1016/j.cancergen.2015.09.002
dc.identifier.pmid26481832
dc.identifier.urihttp://hdl.handle.net/20.500.14038/43754
dc.description.abstractRecent consortium guidelines support research-based screening for those at high risk of pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC)). Genetic testing plays an important role in the establishment of high-risk PDAC research clinics by delineating those individuals who would benefit from screening protocols. We retrospectively examined patients referred for PDAC-related genetic testing from January 2009 to June 2014. Patients were referred for a personal and/or family history of PDAC or a questioned diagnosis of hereditary pancreatitis (HP). Of the 75 referred patients, 36 underwent testing, of which 11 (31%) were mutation-positive. In total, 36% of patients with chronic pancreatitis carried a mutation, 11% of patients with a family history of PDAC carried a mutation, and 20% of patients with a personal history of PDAC carried a mutation. The most common barrier to testing was lack of insurance coverage. Genetic testing yields a suitable number of mutation-positive individuals who may benefit from increased screening. Subjects with possible HP yielded the highest positive rate. Individuals with idiopathic pancreatitis, onset of pancreatitis before the age of 30 years, and those with a family history of PDAC should be considered for testing. Sub-optimal insurance coverage remains a major deterrent to obtaining testing.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=26481832&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.cancergen.2015.09.002
dc.subjectGenetic testing
dc.subjectPancreatic cancer
dc.subjectPancreatitis
dc.subjectGenetics
dc.subjectMedical Genetics
dc.subjectNeoplasms
dc.subjectOncology
dc.titleIdentification of genetic risk for pancreatic adenocarcinoma
dc.typeArticle
dc.source.journaltitleCancer genetics
dc.source.volume208
dc.source.issue11
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/peds_pp/67
dc.legacy.embargo2015-11-01T00:00:00-07:00
dc.identifier.contextkey9360724
html.description.abstract<p>Recent consortium guidelines support research-based screening for those at high risk of pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC)). Genetic testing plays an important role in the establishment of high-risk PDAC research clinics by delineating those individuals who would benefit from screening protocols. We retrospectively examined patients referred for PDAC-related genetic testing from January 2009 to June 2014. Patients were referred for a personal and/or family history of PDAC or a questioned diagnosis of hereditary pancreatitis (HP). Of the 75 referred patients, 36 underwent testing, of which 11 (31%) were mutation-positive. In total, 36% of patients with chronic pancreatitis carried a mutation, 11% of patients with a family history of PDAC carried a mutation, and 20% of patients with a personal history of PDAC carried a mutation. The most common barrier to testing was lack of insurance coverage. Genetic testing yields a suitable number of mutation-positive individuals who may benefit from increased screening. Subjects with possible HP yielded the highest positive rate. Individuals with idiopathic pancreatitis, onset of pancreatitis before the age of 30 years, and those with a family history of PDAC should be considered for testing. Sub-optimal insurance coverage remains a major deterrent to obtaining testing.</p>
dc.identifier.submissionpathpeds_pp/67
dc.contributor.departmentDepartment of Medicine, Division of Gastroenterology
dc.contributor.departmentDepartment of Surgery, Division of Surgical Oncology
dc.contributor.departmentDepartment of Pediatrics, Division of Genetics
dc.source.pages559-63


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record